B

BIOFORGE

Section 01

Executive Summary

Full longevity platform for men who train

TL;DR

BioForge is a longevity platform for men aged 30-55 who train. We help them stay fit, recover faster, and live longer through a free health quiz, an AI-powered app, blood work with 100+ biomarkers, prescription peptides, and dedicated medical teams. Starting from $0 (free quiz) up to $50K/year (concierge medicine), we fill a gap nobody owns: affordable testing AND treatment in one place. We start with $22K and target $40M revenue by Year 5.

Target Market (TAM)

$7.8T

Global longevity economy by 2030

Year 5 Revenue Target

$40M

Blended from all tiers

Gross Margin Target

68%

Blended across value ladder

Initial Investment

$22K

Self-funded, Medvi-style launch

BioForge is a full longevity platform for men 30-55 who train seriously and want to perform at their peak for decades. We help men stay fit and live longer through blood tests, personalized AI recommendations, and prescription peptides — all in one app, starting with a free quiz. Our value ladder runs from $0 (free health quiz) to $50K/year (elite concierge medicine with a dedicated medical team). We fill the gap nobody owns: Function Health does testing ($2.5B valuation) but no treatment, Lifeforce does treatment but weak diagnostics, Fountain Life does both but costs $20K/year. BioForge gives men comprehensive testing AND treatment starting at $365/year for blood work. Operating from Dubai with AI-first operations and outsourced telehealth infrastructure, self-funded with $22K.

Why Now?

FDA Peptide Reclassification (Feb 2026)

HHS Secretary RFK Jr. announced ~14 of 19 previously banned peptides (BPC-157, TB-500, Thymosin Alpha-1, etc.) will return to legal compounding status under Category 1. This reopens a massive market that was restricted since 2023.

Nobody Owns the Middle Market

Function Health ($2.5B valuation, 100K members) does testing but NO treatment. Lifeforce (Tony Robbins) does treatment but weak diagnostics. Fountain Life does both but costs $20K/year. The $500-$3,000/year sweet spot with both testing AND treatment is wide open.

Proven Model — The Medvi Precedent

Medvi demonstrated that a 2-person team can generate $401M in revenue (2025) and $1.8B annualized run rate using telehealth-as-a-service infrastructure, AI-generated marketing, and zero employees in regulated functions. The playbook works.

AI Cost Reduction + Quiz Funnel Revolution

AI tools have reduced the cost of building a full-stack DTC brand by 90%+. Quiz funnels achieve 70-80% completion rates and 40-60% lower CPA than traditional funnels. What required 50+ employees in 2020 can now be done by 2-5 people with AI.

Competitive Advantages

  • 1Full value ladder from $0 to $50K/year — one platform, not scattered services
  • 2Quiz funnel as primary acquisition: 70-80% completion, 40-60% lower customer acquisition cost
  • 3Blood work at $365/year with 100+ biomarkers (cost $50-100, margin 75-85%) — the gateway drug to the platform
  • 4Men-only positioning: sharp brand identity vs. generic telehealth platforms (Hims started men-only too)
  • 5AI-first operations reducing overhead by 80%+ vs. traditional telehealth
  • 6Self-funded bootstrap — no VC pressure, profitable early, reinvest into growth
  • 7Dubai free zone structure enabling global distribution with 0% corporate tax